New Posts New Posts RSS Feed - New Clinical Trial/Research: PARP1 & Trip-Neg
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

New Clinical Trial/Research: PARP1 & Trip-Neg

 Post Reply Post Reply
Author
Joan2844 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jul 03 2007
Location: United States
Status: Offline
Points: 163
Post Options Post Options   Thanks (0) Thanks(0)   Quote Joan2844 Quote  Post ReplyReply Direct Link To This Post Topic: New Clinical Trial/Research: PARP1 & Trip-Neg
    Posted: Oct 23 2007 at 10:46am

Hopefully this information can help some:

 

BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer

BRISBANE, Calif., Oct. 22 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that key data supporting its PARP (poly-ADP-ribose polymerase) inhibitor drug development programs will be presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco from Oct. 22 to 26 and the EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" in Brussels, Nov. 15 to 17.

PARP is a novel, validated target for cancer treatment. PARP1 plays a central role in cell proliferation and in DNA repair. BiPar scientists will present results showing that PARP1 gene expression is significantly upregulated in many but not all tumor types. BiPar's novel, proprietary PARP inhibitors are members of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit tumor cell proliferation and are active against a broad range of tumor types. BiPar is initiating Phase 1b and Phase 2 clinical trials of BSI-201, its lead PARP inhibitor, in several major cancers. That research program has been directed in large part by the molecular biomarker data being presented at these meetings.

"These findings will focus our efforts on those tumor types with the greatest opportunity for clinical success," said Barry Sherman, M.D., BiPar's executive vice president. "With this information we believe we will be able to efficiently exploit our pipeline of PARP inhibitors that target major unmet needs in cancer."

The schedule of presentations is as follows: Title: The novel PARP-1 inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotopic activity in human pancreatic cancer When: Wednesday, Oct. 24, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Davide Melisi, M.D., Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center Title: PARP-1 gene over-expression in primary human cancers: A potential marker for PARP inhibition. When: Thursday, Oct. 25, 2007, 12:30 p.m. PDT Where: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Moscone West Convention Center, San Francisco Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar Title: The PARP1 gene is over-expressed in triple negative breast cancer When: Thursday, Nov. 15, 6 to 8 p.m. CEST Where: EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer," Sheraton Brussels, Hotel & Towers, Brussels, Belgium Presenter: Valeria Ossovskaya, Ph.D. Director of Preclinical Development, BiPar About BiPar Sciences

BiPar Sciences Inc. (http://www.biparsciences.com/) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.

BiPar Sciences, Inc.

CONTACT: Eric Malek, Vice President of Corporate Development of BiPar
Sciences, 1-650-635-0165, emalek@biparsciences.com; or Brian Reid of
WeissComm Partners, 1-703-402-3626, breid@weisscommpartners.com for BiPar
Sciences

Web site: http://www.biparsciences.com/

 

9/06 Stage2B. Pos Nodes; Neg BRAC; TAC/Lumpectomy/Rads/Xeloda.
4/08 Local Recurrence; Mast w/ Latissimus Flap;Taxol/Gemzar/Carbo. Zometa.

NED since May 2008 :-)
www.wow-matt14.blogspot.com
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.